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The animal health ﬁeld provides a unique opportunity for the appli-
cation of plant-derived immunotherapeutics and vaccines. Infectious
diseases have historically been a major cause of economic loss to the
livestock industry worldwide, both directly as well as through dis-
ruptions in international trade. For example, bovine spongiform en-
cephalopathy (mad cow disease) cost the Canadian beef and dairy
industries over $5.3 billion in the two years following the identiﬁcation
of the ﬁrst infected animal (Statistics Canada, 2006). Likewise, there are
numerous other zoonotic pathogens, such as Escherichia coli O157,
which do not affect the health of animals yet result in economic losses
due to outbreaks of disease in human populations. A growing desire to
control such pathogens is evident in public health initiatives such as
One Health bwww.onehealthinitiative.com/N, an international effort to
expand collaboration across healthcare for humans, animals, and the
environment. Of course, a multitude of economically important veteri-
nary diseases exist that are not of signiﬁcant risk to humans: notably
foot-and-mouth disease, Newcastle disease, classical swine fever, por-
cine reproductive and respiratory syndrome, and porcine epidemic
diarrhea.
Vaccines have the potential to reduce the burden of animal infec-
tions, but in many cases vaccines have not been produced that are
both effective and cost-saving for the livestock industry. For example,
a vaccine against E. coli O157 (Canadian license issued in 2008, now in-
active) for use in cattle has a projected capacity to reduce human cases
by nearly 85%, yet adoption of this vaccine by farmers was low
(Matthews et al., 2013). Low adoption rates were due both to the cost
of the vaccine and the need to handle animals three times for vaccine
administration. Production of lower-cost vaccines in plants combined
with oral administration by incorporating the product into livestock
feed may be an avenue to increased adoption.
Although the concept of plant-derived veterinary vaccines dates
back to 1993 (Usha et al., 1993), such vaccines are yet to be available
on the market. Interest in the use of transgenic plants for pharmaceuti-
cal production has been growingover the pastﬁve years (Fig. 1); and in-
terest in veterinary vaccines, in particular, has been increasing because
regulatory approval can be signiﬁcantly less onerous than that for
human pharmaceuticals (Phan et al., 2013). Themotivation for produc-
tion of vaccines and other biologics from plants arises from an array of
potential advantages over other production systems (Kolotilin et al.,
2014). Depending on the plant system used, these advantages can in-
clude relatively high expression levels; effective post-translational
modiﬁcations including proper folding and glycosylation; lower risk ofcontamination with animal pathogens or bacterial toxins; cost-of-
production efﬁciencies; speed of development in the case of transient
expression; stable, room temperature storage within seeds and oral ad-
ministration of the product (Everett et al., 2012; Kolotilin et al., 2012;
Tremblay et al., 2010).
Plant production platforms are diverse, and may involve the use of
whole plants in a greenhouse or ﬁeld, or plant cell culture; stable or
transient expression; targeted or constitutive expression; expression
from nuclear or organelle genomes; and expression of protein mono-
mers,multimers, or virus-like particles. In addition, the unmodiﬁed ver-
sion of the engineered plant may be a food or feed crop, or neither. The
product may be intended for puriﬁcation, or administration as a crude
extract or whole plant tissue, and the planned route of administration
may be oral, nasal, topical, or through injection. These factors all inﬂu-
ence the advantages of the plant-based system, and can affect the
steps in the commercialization process of a potential plant-made prod-
uct. For example, while oral immunization is likely to be more conve-
nient for the end-user, it often necessitates a very large dose to elicit
the desired response, requiringmilligramor gramquantities as opposed
to the micrograms needed for injectable delivery (Rybicki, 2010).
Several excellent references for varied topics of interest for the com-
mercialization of plant-made pharmaceuticals have recently been pub-
lished. For products and platforms, a large array of plant species and
Fig. 2. Approximate chronology for company activities and investments. Divisions among
levels are arbitrary. Question marks (?) indicate activities that may be undertaken at the
subsequent level (i.e. level x + 1), or may not be undertaken by the company.
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make antibodies, vaccines and cytokines is presented by Tremblay
et al. (2010); while recombinant plant-made cytokines are the focus
of Sirko et al. (2011); and the plant-based production of antibodies for
passive immunization is reviewed by Virdi and Depicker (2013). Plant
cell suspension cultures from tobacco, rice, barley through to moss
and the mechanics of bioreactor production are reviewed by Huang
and McDonald (2012); and seed, leaf and cell bioreactor systems plus
protein puriﬁcation concerns are reviewed by Wilken and Nikolov
(2012). Production of plant made veterinary vaccines with an example
of puriﬁcation using elastin like polypeptide fusions (ELPylation) is
reviewed by Phan et al. (2013), and a unique puriﬁcation method
using hydrophobins from ﬁlamentous fungi is presented in Joensuu
et al. (2010). Multiple plant transformation methods other than
Agrobacterium transfer are effectively surveyed by Rivera et al. (2012),
and the potential for higher yielding recombinant protein expression
using chloroplast transformation is outlined in Bock and Warzecha
(2010) and Scotti et al. (2012). An important potential strength of
plant-based production may be the utility in oral delivery of edible vac-
cines with protein body-like encapsulation for gastrointestinal presen-
tation, as previously reviewed (Jacob et al. 2013; Khan et al. 2012;
Kwon et al. 2013). Mucosal, oral provision is being sought for low cost
and ease of use without the need for refrigerated storage and transpor-
tation and has gained considerable international interest (Pelosi et al.
2012; Rybicki et al. 2012).
Although motivation is great, a knowledge gap exists between the
ability to create and evaluate plant-based products in the laboratory,
and the ability to take these products on a path to commercialization,
including business planning, ﬁnancing, and regulatory approval. This
report provides guidance relevant to this process as an aid in planning
for the commercialization of plant-made vaccines and biologics for
veterinary use. Some of the content, especially that dealingwith regula-
tory issues, has a Canadian focus consistent with the authors' expertise.
However, information is provided that is relevant to multiple countries.
The hope is that the information here will help more scientists get the
products of innovation from the bench, to the ﬁeld and to the animal.
2. Business planning
2.1. Collaborations
Sincemost scientists do not have sufﬁcient ability or time to dedicate
to ﬁnancing and commercialization of technologies, an important step
toward success is partnering with entrepreneurs or business associates
to successfully ﬁnance and commercialize ideas.
The company's topmanagement teammay include a chief executive
ofﬁcer (CEO), chief operating ofﬁcer (COO), chief ﬁnancial ofﬁcer (CFO),
and chief scientiﬁc ofﬁcer (SCO), among others. Ideally, the team will
have afﬁliations with prominent downstream organizations and with
a diverse range of organizations (Higgins and Gulati, 2006). The CEO is
head of this top management team, and deals with strategic, long-
term challenges of the company. The COO is an optional, second-in com-
mand position, usually deﬁned in relation to the CEO. He/shemay act as
co-leader; lead the implementation of speciﬁc strategies, such as change
or expansion; or provide advice to a more inexperienced CEO (Bennett
and Miles, 2006). The CFO creates budgets, evaluates business unit per-
formance, and acts as a primary ambassador to investors (Zorn, 2004);
while the CSO is responsible for developing research capabilities and
evidence of the viability and utility of products, and his/her role and ex-
perience, in particular, can affect investor decisions (Higgins and Gulati,
2006).
A proper company will also require a board of directors or gover-
nors, to show the public that the company has sound governance and
will manage its investments in a highly responsible, productive and
professional manner. The board is a small group of individuals often
consisting of one or two members of a company's executive, but it ismandatory that outside members are included, and these should be
established professionals easily recognized by the public as individuals
who are honest, capable of delivering results, andwho have impeccable
integrity.2.2. Creating a business plan
A business plan is essential for commercialization. It is a manage-
ment tool that outlines the company's activities and plans for success,
and becomes the foundation on which business ofﬁcers rely to seek
ﬁnancing. Such a document usually takes a large number of iterations
before being ﬁt to present to potential investors.
A typical plan for a biotechnology company will include a descrip-
tion of the commercial opportunity that the company is developing; a
thorough but easy-to-understand description of the technology that
will be used; a sound business model (how the company will make
money); a description of the market or markets that products will tar-
get; a complete description of the competition that is already in place,
or the likely competitors whowill also beworking in the same business
space; strategies for investors, including a description of entry and exit
points, as well as corporate strategies; the company's intellectual prop-
erty (IP) plan, including a description of all patents currently held, those
under development and the company's policy on freedom to operate
(FTO); a ﬁnancial review with projected proﬁt and loss considerations
as well as the company's plan for immediate and long-term cash ﬂow;
and a description of the regulatory requirements for products and
waste materials (which is of particular importance in the area of thera-
peutic bioproducts).2.3. Financing
Financing must be considered at all stages, from concept develop-
ment to ﬁnal sales (Fig. 2), and it is an increasingly challenging and on-
going process. Financing requirements expand tremendously as a
company grows from its beginnings toward product sales. Many of the
members of a company's executive are usually involved in fundraising,
including most or all of the chief ofﬁcers.
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ders, as well as investment from family and friends, research grants,
and in-kind donations from an afﬁliated university or research institu-
tion. Investment from founders provides themwith control of the com-
pany and gives subsequent investors faith that the founders are serious
about the new company. Investors will be offered shares of company
stock at ﬁxed prices as outlined in the business plan, and there can be
several series of preferred stock that are offered to investors before a
company becomes a public entity and starts to sell or trade shares on
an open market. Tax credits from local, provincial or federal sources
are another source of revenue which should be sought. Additional
opportunities could include income from contract research or produc-
tion, or being sponsored by a larger and established company or a gov-
ernment agency. Initial activities supported by early ﬁnancing should
include concept development, development of a strong business plan,
provision of supporting research data, development and protection
of intellectual property (IP), and the hiring and training of technical
personnel.
Invariably, fund-raising requires going beyond ﬁrst-stage investors
to seek further capital from “angel” investors. Angel investors are
wealthy individuals or groups who are looking for start-up investment
opportunities that allow for tremendous ﬁnancial gain should the new
enterprise become successful. Local communities often have investor
meetings or clubs, such as those which might be hosted by a chamber
of commerce. There are also many angel groups who advertise on the
internet. Angel investors can provide substantial funding for technology
reﬁnement and process development, as well as for in vivo experimen-
tation to demonstrate the efﬁcacy of company technology. Other oppor-
tunities to ﬁnd investment can come from networking at trade shows,
or presenting at forums held by local, state, or provincial governments.
These are often associated with ministries or departments that serve to
promote technology transfer. Federal governments can also promote
new companies through consulate- or embassy-associated investment
meetings in foreign countries.
A third level of investment can include venture capital, partnerships,
and entering into the stockmarket. Entry into a public stockmarket is a
major step for a new company; however, this process usually occurs
after all sources of venture capital investment are exhausted. Partnering
with established companies for production,marketing and sales is often
required. Activities include, but are not restricted to, establishment of
company infrastructure, safety and efﬁcacy trials, production and mar-
keting. Next-product developments are also key to company growth.
3. Market viability
3.1. Target market & competitors
In order to attract collaboration and investment, and to make sure
that a proposed product has a place in the market, an early step is to
assess the value of the product and thepotential for competition. Invest-
ment in a vaccine candidate depends on ﬁnancial return on research
and development investment, and this return depends to a large extent
on the novelty of and need for the product. As average timelines for
research, development, and registration of a novel product range from
ﬁve to seven years (International Federation for Animal Health [IFAH]
Europe, 2008), the target markets should be predicted at least this far
in advance. Eventual and long-term consumer acceptance must also
be gauged ﬁve to ten years in advance.
A key driver for a new product opportunity is the identiﬁcation of
end-user needs, including convenience of administration, conﬁdence
in positive safety and efﬁcacy outcomes, and the cost or return on in-
vestment for the end-user's use of the product. A target proﬁle which
will meet end-user requirements must be identiﬁed, including the
targeted label claim (prevention of disease X caused by organism Y);
product attributes that can differentiate it in the market, like an easier
route or method of administration (e.g. single vs multiple-dose;intranasal, oral, or parenteral administration); and the potential market
value, including estimation of the total target market and the potential
market share (IFAH Europe, 2008). The product proﬁle should also
align with existing management practices and consider the minimum
vaccination age, the route and interval of administration, as well as
the desired onset and duration of immunity. The effect of maternal an-
tibodies on vaccine performance should also be considered. The
targeted market may be a large, widespread need across multiple spe-
cies (e.g. leptospirosis; inﬂuenza) or a small niche where no or few
products are currently available. Emerging infectious diseases (e.g. por-
cine epidemic diarrhea syndrome) can also be a prime area of market
development. Market opportunities may also arise from efﬁcacy con-
cerns with current disease management options, or safety concerns
with existing products.
As part of the market assessment, potential competitors need to be
identiﬁed and evaluated against the proposed product. The easiest and
least expensive place to start is by internet-based searching for research
focused on the same disease areas and targets, as well as those using
similar technologies or platforms. Afﬁliations and acknowledgements
for published peer-reviewed research can identify relevant academia-
industry ties that may already exist. Searches of patent literature will
provide information on the intellectual property landscape for areas of
interests (see Section 3.3) as well as identify potential competitors.
Additional information can be gathered from networking at relevant
conferences and meetings.
3.2. Product development
For a new plant-based vaccine candidate at the research stage, an
important milestone is proof-of-concept to show that the candidate is
safe and efﬁcacious using research batches produced at very small scale.
For commercial-scale production, however, the manufacturing scale-up
and quality control must demonstrate that the vaccine can be produced
in a manner that minimizes batch-to-batch variability and the potential
for batch rejection due to inadequate quality (USDA-APHIS, 2014a). This
development phase is lengthy and expensive; therefore the feasibility
of scale-up is a key factor that should be considered early in the
vaccine development process. The cost of goods must be consistent and
favorable to ensure continued proﬁtability for the manufacturer and
cost-effectiveness for the customer. These costs should be included in
analyses along with the availability and cost of commercial production
facilities. If production facilities are unavailable, the cost to build and
certify production facilitiesmust be included. Note that individualmarket
differences inmanufacturing site requirementsmay reduce economies of
scale, thus increasing product costs (IFAH Europe, 2008).
While oral delivery of the vaccinewithout puriﬁcation is expected to
be most economically advantageous for product development and use,
certain products may require puriﬁcation. In such cases, downstream
processing of plant-made immunotherapeutics can account for up to
80% of production expenses (Fischer et al., 2012) with hidden costs for
processes such as buffer preparation and equipment cleaning, tests to
validate the effectiveness of cleaning parameters, and activities relating
to product quality control and assurance. Validation, quality control, and
quality assurance can account for over 50% of labor costs (Wilken and
Nikolov, 2012). An acceptable product shelf-life is also critical for logis-
tics and inventory management, both for the manufacturer and for the
end-user. Even so, it is estimated that with 1% protein expression and
50% protein recovery from puriﬁcation, the cost of plant based protein
is 10 and 1000 fold lower thanmicrobial andmammalian based expres-
sion systems, respectively (Xu et al., 2012).
Post-licensing activities should also be considered. Reference
requaliﬁcation studies are needed to ensure the continued potency
and efﬁcacy of the product (USDA-APHIS, 2011). Vaccinovigilance pro-
grams are invaluable in monitoring and ensuring continued ﬁeld safety
of the product; data arising from these activities can determine if label
statements or use recommendations need adjustment to ensure safety
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support the product's use in smaller markets or unique geographic or
husbandry areas. Finally, further development programs may have to
be initiated to expand the product's label claims in order to address
evolving market needs or animal management practices (e.g. use in
pregnant animals; decreased volume of vaccine doses).
Certain go/no-go points during product development should also be
considered, with possible exit strategies for each, such as commercial
licensing of products/services, or the sale of companies/technologies
to strategic investors such as pharmaceutical companies or mature
biotechnology companies. Commercial licensing of vaccines effective-
ly enables the sale of each product as it arises, while preserving the
core technologies associated with vaccine production for future dis-
coveries. Given the highly technical nature and speciﬁc expertise re-
quired for production of plant-made vaccines, a licensing strategy
may offer the highest probability of success. This is particularly
true in today's business climate, where roughly 60% of new products
are licensed from third parties. However, there is no standard tem-
plate, with potential partners interested in anything that adds
value to their pipelines or provides a market advantage. This in-
cludes know-how, technology or products. Ultimately, success can
be measured by ﬁnancial return, vaccine approval, vaccine sales
and/or market share.
3.3. Intellectual property
Intellectual property (IP) considerations are an important compo-
nent in bringing technologies to market and must be looked at from
the planning stage all the way through commercialization, with advice
from an IP professional. They play a key role in assessing the novelty
of a proposed product, the potential competition, and the ability to pro-
duce and market the product without infringing on the rights of others,
also known as “freedom to operate” (FTO). For very early stage research,
a preliminary approach to identify themajority of relevant existing pat-
ents, using free online resources, may be beneﬁcial (Miralpeix et al.,
2014).
Once a potential IP asset is created, a patent or other form of protec-
tion may be needed in order to prevent others from using the ideas for
their own gain. In the case of a plant platform in combination with a
chosen antigen, the IP landscape is complex, and continually changes
over time as technologies mature and patent ofﬁce rules and guidelines
change. For example, the ﬁrst claim from a patent allowed in 1997
(resulting from a ﬁling made in 1988) was very broad:
A transgenic plant, comprising and expressing a DNA sequence cod-
ing for an antigen of a pathogenicmicroorganism or an antigenic de-
terminant thereof, said antigen or antigenic determinant thereof
eliciting a secretory immune response in a human or other animal
upon oral administration of tissue of said plant (Curtiss and
Cardineau, 1997);
A more recently issued patent is likely to be signiﬁcantly more nar-
row, such as this ﬁrst claim from a patent allowed in 2011 (resulting
from a ﬁling made in 2007):
A method of inducing an immunoprotective response against a
strain of Avian Inﬂuenza Virus (AIV) in an animal or human which
comprises; a) expressing in a plant cell a DNA sequence encoding
a hemagglutinin (HA1) variable region polypeptide comprising
SEQ ID NO: 1 or 7; b) preparing a vaccine composition using the
HA1 variable region polypeptide expressed in said plant cell;
c) administering said vaccine composition to an animal or human
such that a protective immune response is induced in said animal
or human; and d) exposing said animal or human to a challenge
strain of AIV having a HA1 variable region polypeptide that has at
least 70% and less than 85.0%, sequence identity to SEQ ID NO: 1 or
7 (Webb and Henry, 2011).The breadth of what one can obtain in a patent claim is much
narrower than it used to be. While the reasons for such narrowing are
many, the standards for obtaining a broad patent claim are now quite
high. The principle that a patent speciﬁcation must be sufﬁcient to en-
able one skilled in the art to practice the invention is now strictly
enforced. This was not the case several years ago and as a result broad
claimswere allowed without the inventors truly enabling the invention
through the speciﬁcation.
Complexity in both IP protection and FTO stems partly from the fact
that the technology crossesmultiple ﬁelds of innovation, such as genetic
transformation and transient expression in plants including all the
cloning, delivery, marker systems, etc.; protein engineering; antigen
production; extraction and processing; adjuvant, formulation, and im-
munotherapy (Biodesign Institute, 2005). This means that there may
be several IP hurdles to overcome when attempting to bring a product
to market, as FTO across all of these ﬁelds must be considered. An FTO
assessment for plant-based vaccines can therefore comewith a high de-
gree of uncertainty when large numbers of patents have to be consid-
ered (Krattiger and Mahoney, 2007). One must also consider patents
that have just been recently applied for, not just those which have
been issued. An FTO assessment should be continually revisited as
there is generally an 18month time period in which patent applications
are not made public, and court decisions have impacted biotechnology
patents signiﬁcantly over the years. Protecting IP through a patent
when there is already substantial prior art in the areameans that claims
will likely be narrow as in the example above.
While manageable, navigating the complexity takes time and can
add substantial costs that offset the advantages of plant-based systems.
There are several strategies that potentially can help keep costs down
such as exploiting nichemarkets, workingwith off-patent technologies,
cross licensing, partnerships, and others. If there is no opportunity to
work around a technology one can look at acquiring, or licensing IP.
An IP owner is not required to license their technology but many wish
to recoup the costs they've incurred protecting their IP. There is a
good chance a license will be needed at some point given the broad
range of technologies involved in producing a plant-derived vaccine or
therapeutic.
The Patent Cooperation Treaty (PCT) provides an internationally
uniﬁed procedure for ﬁling patent applications, but each country or
region prosecutes applications and issues patents. Parties also accept
patent applications directly without going through the PCT process.
When choosing jurisdictions one needs to look at protection where
the product will be made and sold. Global protection is not necessary
if markets are geographically limited. In general, cost savings may be
achieved by ﬁling a PCT application if one requires patent coverage in
many jurisdictions, while direct ﬁlings to state ofﬁces will cost less if
fewer jurisdictions are needed. However, not all countries are party
to the PCT, such as Argentina and some members of the European
Union.
In protecting an IP asset one might want to consider keeping the IP
as a trade secret instead of seeking patent protection. A trade secret by
deﬁnition is something that is not disclosed publicly and can last indef-
initely as long as the information does not become known. Unlike a pat-
ent, there is no protection once information related to a trade secret is
disclosed. In the ﬁeld of plant vaccines trade secrets might be in the
form of know-how with respect to a processing facility or scaling up a
technology. Protecting the trade secret would mean limiting access to
a facility. The following link provides a good discussion on the advan-
tages of trade secrets compared with patents: bhttp://www.wipo.int/
sme/en/ip_business/trade_secrets/patent_trade.htmN
Further information on IP fundamentals is covered by patent ofﬁces
and other online resources:
http://www.wipo.int/about-ip/en/
http://www.epo.org/learning-events.html
http://www.uspto.gov/
http://www.patentlens.net/
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4.1. Overview
As is the case with IP and FTO, regulations for plant-based vaccines
can be complicated by the intricacy of technology, and requirements
are changing to keep pace with technological advances. The develop-
ment of transgenic crops has pushed countries to develop regulations
that address public concerns about food, feed and environmental safety
while still allowing access to these crops for growers. Ideally, the regu-
latory framework should be constructed to adequately address safety
concernswhile fostering the development and deployment of transgen-
ic crops inside a country. Regulatory frameworks have emerged that are
based either on the process of genetic engineering, or on the ﬁnal
product.
Regulations regarding transgenic plants in the European Union,
which are possibly the most restrictive, use a strongly precautionary,
process-based approach (Sparrowet al., 2013). In addition, once a trans-
genic plant is approved, Member States have the ability to opt out of
allowing the plant to be cultivated or used as food or feed based on
“legitimate reasons” other than risks to health or the environment, butTable 1
Regulators responsible for aspects of plant-made veterinary vaccines in various countries. AFD
Plant Health Inspection Service; APVMA, Australian Pesticide and Veterinary Medicine Authori
Canadian Food Inspection Agency; CONABIA, National Agricultural Biotechnology Advisory Com
culture, Forestry and Fisheries; DBT, Department of Biotechnology; EC, European Commission;
Drug Administration; FSSAI, Food Safety and Standards Authority of India; GAQSIQ, General Ad
China; MAPA,Ministry of Agriculture, Livestock, and Food Supply;MOA,Ministry of Agriculture
ests; MOHFW, Ministry of Health and Family Welfare; MOST, Ministry of Science and Technolo
Biosafety Administration; OGTR, Ofﬁce of the Gene Technology Regulator; PBO, Plant Biosafety
Service of Health and Agrifood Quality; USDA, United States Department of Agriculture.
Regulatory aspect Regulators
Canada USA EU
Plants grown in containment Environment
Canadaa
USDA-APHISb Member state
authoritiesc
plant ﬁeld trials CFIA-PBOh USDA-APHISc Member state
authoritiesc
Commercial release of plants CFIA-PBOh USDA-APHISc Member state
authorities, EC, EFSAc
Vaccine safety & efﬁcacy CFIA-CCVBj USDA-APHISk member state
authorities, EMAc
Use in livestock feed CFIA-CCVB,
CFIA-AFDq
USDA-APHISr
FDAc,k
member state
authorities, EC, EFSAc
Safety of meat, milk and eggs
derived from treated livestock
Health
Canadau
FDAv member state
authorities, EC, EFSA,
EMAw
a Canadian Environmental Protection Act, 1999.
b USDA-APHIS, 2007.
c Sparrow et al., 2013.
d Chenault Chamberlin, 2010.
e Chen et al., 2011.
f Choudhary et al., 2014.
g Tribe, 2012.
h CFIA, 2012a.
i OGTR, 2001.
j CFIA, 2014b.
k USDA-APHIS, 2013.
l MAPA Strategic Management Ofﬁce, 2010.
m MOA, 2009.
n MOHFW, 2005.
o APVMA, 2008.
p SENASA, 2010.
q CFIA, 2014d.
r USDA-APHIS, 2014b.
s BIS, 2014.
t DAFF, 2013.
u Health Canada, 2013.
v FDA, 2014.
w European Parliament and the Council of the European Union, 2009.
x GAQSIQ, 2007.
y MOHFW, 2011.
z APVMA, 2014.including cultural traditions (European Commission, 2015; European
Parliament and the Council of the European Union, 2015). In contrast,
the regulatory framework for genetically engineered plants in the USA
is product-based, arising from the premise that genetically engineered
organisms are not inherently risky (Sparrow et al., 2013). Uniquely,
the Canadian system regulates transgenic plants as “plants with novel
traits”; a classiﬁcation based entirely on the presence of a newly
expressed trait, regardless of the method of introduction (CFIA, 2014a).
Regulatory responsibilities are generally divided between various
government departments and sometimes non-governmental expert
bodies. There are differences between countries in terms of the author-
ities responsible for implementing regulations (Table 1), the legal
framework that is the basis of regulations, and the regulatory processes.
However, the information guiding risk assessments that underlie the
safe deployment of transgenic crops is very similar.
In Canada, the regulation of plant-produced veterinary vaccines falls
primarily under the authority of the Canadian Food Inspection Agency
(CFIA) (Fig. 3). Within the CFIA, vaccines and their manufacturing facil-
ities are regulated by the Canadian Centre for Veterinary Biologics
(CCVB), feeds by the Animal Feed Division (AFD), and ﬁeld-grown
plantswith novel traits by the Plant BiosafetyOfﬁce (PBO). Distinctively,, Animal Feed Division; ANVISA, National Health Surveillance Agency; APHIS, Animal and
ty; BIS, Bureau of Indian Standards; CCVB, Canadian Centre for Veterinary Biologics; CFIA,
mittee; CTNBio, National Technical Commission on Biosafety; DAFF, Department of Agri-
EFSA, European Food Safety Authority; EMA, European Medicines Agency; FDA, Food and
ministration of Quality Supervision, Inspection and Quarantine of the People's Republic of
;MOAC, Ministry of Agriculture and Cooperation;MOEF,Ministry of Environment and For-
gy; NSS, National Surveillance System; OAGEBA, Ofﬁce of Agricultural Genetic Engineering
Ofﬁce; SAGPyA, Secretariat of Agriculture, Livestock, Fishery, and Food; SENASA, National
Brazil China India Australia Argentina
NSSd OAGEBAe MOEF,
MOST-DBTf
OGTRg SAGPyA-CONABIAd
NSS,
CTNBiod
OAGEBAe MOEF,
MOST-DBTf
OGTRg,i SAGPyA-CONABIAd
NSS,
CTNBiod
OAGEBAe MOEF,
MOST-DBTf
OGTRg SAGPyA-CONABIAd
MAPAl MOA-Veterinary
Bureaum
MOHFWn APVMAo SAGPyA-SENASAp
MAPAl MOA- Veterinary
Bureaum
BIS (not
compulsory)s
DAFF,
APVMAt
SAGPyA-SENASAd,p
MAPAl MOA- Veterinary
Bureaum, GAQSIQx
MOHFW-FSSAIy APVMAz SAGPyA-SENASAp
Fig. 3. Flowchart for regulatory approval of plant-made vaccines in Canada. Under the authority of the CFIA, vaccines and their manufacturing facilities are regulated by the CCVB, feeds by
the AFD, and ﬁeld-grown plants with novel traits by the PBO. Risk assessment for the environmental release of aquatic plants with novel traits is the responsibility of Fisheries and Oceans
Canada (Fisheries and Oceans Canada, 2007, 2014). Approval is required from all relevant regulatory parties (e.g. if a plant that produces a vaccine is to be grown outdoors and adminis-
tered to livestock by incorporating the product into feed, then the CCVB, AFD, and PBO must be consulted). While the CCVB, AFD, and PBO will share information, it is ultimately the re-
sponsibility of the applicant to contact, and obtain approval from, all relevant ofﬁces (CFIA, 2012a). aApplications to the PBO compare the product to a plant with a history of safe use (CFIA,
2014a). Aspects of the modiﬁed plant that are determined to be equivalent to the counterpart are accepted and the assessment then focuses on the differences (CFIA, 2014c). bNote that,
due to the nature of the product, plants that produce vaccines or other pharmaceutical compoundsmay need to be grown under physical and reproductive conﬁnement, even during com-
mercialization (CFIA, 2012a).
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novel traits is the responsibility of Fisheries and Oceans Canada
(Fisheries and Oceans Canada, 2007, 2014). Approval is required from
all relevant regulatory parties depending on the intended use and re-
lease of the product. For example, if a plant produces a vaccine that is
to be administered to livestock orally via feed, and the plant is to be
grown in the ﬁeld, then the CCVB, AFD, and PBO must all be consulted.
Even if a vaccine-producing plant is not intended for use as feed or
food, if its unmodiﬁed counterpart is a source of feed or food, assess-
ment would require consultation with the AFD or the Novel Foods
Section of Health Canada, respectively, to weigh potential risks associat-
ed with the release of the product into a commodity stream for which it
is not intended (CFIA, 2014c). The CFIA, therefore, has historically dis-
couraged molecular farming in major feed or food crops, as well as in
crops pollinated by bees that contribute to commercial honey produc-
tion (CFIA, 2015). While the CFIA allows ﬁeld trials in food and feed
crops, it imposes greater isolation distances for such crops (see
Section 4.4) (CFIA, 2015).
4.2. Vaccine safety & efﬁcacy
According to the CFIA, veterinary vaccines are categorized as veteri-
nary biologics, a classiﬁcation which also includes antibodies used to
treat or prevent disease in animals. For approval in Canada, a veterinary
biologic must meet the following general criteria:
– The productmust be pure, i.e., prepared to a ﬁnal form and relatively
free of extraneous micro-organisms and extraneous material, as
determined by established test methods and approved in theproduction outline (CFIA, 2012b).
– It must be safe, potent and efﬁcacious.
– Each biologically active component must be relevant to infectious
animal disease conditions and animal genetics in Canada.
– The product must be manufactured in a facility acceptable to the
Canadian Centre for Veterinary Biologics (CCVB)
– The productmust be produced and tested in accordancewith gener-
ally accepted good manufacturing practices and quality assurance
standards (CFIA, 2014b).
Preliminary proof-of-concept data to support safety and efﬁcacy
must be submitted with an initial product ﬁle, which will trigger a
phased review (Fig. 3). Preliminary approval from the CFIA–CCVB is
needed prior to conducting further studies under contained conditions
to support product potency, efﬁcacy and safety. For use of experimental
biologics in ﬁeld studies outside of biocontainment facilities, a Permit to
Release Veterinary Biologics (PRVB) is required (CFIA, 2014b). Approval
of the PRVB is based on an environmental assessment, and would
include consideration of the potential transfer of residues into the envi-
ronment through excreta from the livestock consuming the product,
and othermechanisms; and the potential forworker or bystander expo-
sure (CFIA, 2013, 2014c). The CFIA-CCVB will also assign withdrawal
periods to the vaccine based on the potential of vaccine, adjuvant or
excipient residues to persist in livestock, including in the meat, milk,
or eggs. Approval of any meat, milk, or eggs from vaccinated livestock
is further subject to a food safety review from Health Canada.
Approval of a facility to manufacture veterinary biologics is also re-
quired. This involves a review of the facility, personnel, manufacturing
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inspection of all premises where manufacturing, testing, preservation,
packaging, labeling, storage and distribution of the biologic are
performed (CFIA, 2014b).
If the plant-made vaccine, whether in whole plant tissue such as
leaves or seeds or as puriﬁed protein, is incorporated into feed for oral
administration, the feed product will also need to be registered under
the Feed Act and Regulations after approval of the vaccine component
by the CCVB (CFIA, 2014d; Fig. 3). A product intended to be both a vet-
erinary biologic and a feed would be classiﬁed and regulated primarily
as a biologic by the CCVB, according to an established hierarchy for
products with multiple claims (CFIA, 2014e); however, the CCVB may
coordinate a joint review involving the AFD for approval (CFIA, 2014d,
2014e).
4.3. Environmental risk assessment
The living plants that produce a vaccinemust also bemaintained in a
way that is safe for the environment. For transgenic plants, the environ-
mental risk assessment generally estimates the risks associated with
their release and cultivation in comparisonwithwild type plants. Coun-
tries with established regulatory programs for environmental risk as-
sessment of transgenic plants consider similar safety concerns to be
important, and these are addressed on a case-by-case basis prior to
commercialization. Documents such as the OECD consensus documents
(OECD, 2014) provide guidance on the array of potential concerns that
are considered and their use in environmental safety assessment. The
common considerations for the safety assessment of any transgenic
plant would also apply to the safety assessment of plants producing a
vaccine. These concerns generally include: gene transfer to related
species; changes in weediness potential; secondary (indirect) and
non-target adverse effects; and enhanced capacity to harbor plant
pests (Macdonald, 2012).
Hazards can potentially exist for non-target organisms including
plants, beneﬁcial organisms (pollinators, biological control organisms,
and soil microbes), and terrestrial or aquatic animals, and these
concerns can increase if there are consequences for endangered or cul-
turally important species. Non-target organisms may be exposed to the
recombinant product through direct ingestion of the transgenic plant, or
ingestion or parasitism of organisms that have fed on the plant. The
recombinant product may itself cause adverse effects, or it may lead
directly or indirectly to the expression of another product that causes
adverse effects. Such effects may include toxicity, allergenicity, or
oral tolerance in wild or domesticated animals (Kirk et al., 2005;
Macdonald, 2012). It is therefore important to identify the threatened,
endangered, and beneﬁcial species that occur in the area where the
plant will be grown. The potential consequences of the transgenic
plant affecting soil micro-ﬂora or faunamust also be considered. Appro-
priate indicator organisms can be chosen based on the potential for ex-
posure to the product under ﬁeld conditions, which would be affected
by tissue-speciﬁc expression (Macdonald, 2012).
Risks to non-target organisms may be studied using a tiered ap-
proach: should adverse effects be observed in the laboratory, ﬁeld stud-
ies may be needed to evaluate the actual abundance of non-target
species that would come in contact with the transgenic plant. For in-
stance, compared to laboratory test doses, insects are normally exposed
to smaller amounts of toxins in the ﬁeld because of more varied food
choices and other environmental factors (Macdonald, 2012).
Adverse effects to ﬁeld workers could also arise through physical
contact with the transgenic plant, or use of the plant, its parts, or prod-
ucts, and need to be evaluated (Macdonald, 2012).
4.4. Contained production & ﬁeld trials
Transient production systems in contained facilities are subject to
oversight by Environment Canada (Canadian Environmental ProtectionAct, 1999), but other Government of Canada departments and provincial
authorities would have oversight of transport to production facilities,
waste disposal and waste water handling.
Conﬁned research ﬁeld trials are regulated by the CFIA (land plants)
or by Fisheries and Oceans Canada (aquatic plants). An essential aspect
of conducting these trials, where potential hazards are incompletely
characterized, is tominimize unintended exposure outside of the desig-
nated ﬁeld trial area. This is achieved by preventing pollen, seed or
propagable materials from escaping the trial area; imposing conditions
of reproductive isolation; assuring that volunteer plants are removed
during the post-harvest period; and requiring that all vegetative or
propagable material is destroyed according to approved methods (e.g.
deep burial, incineration etc.) or securely stored and labeled. Govern-
ment inspectors will inspect during the growing season and in the
post-harvest period to ensure compliance with these conditions. Addi-
tionally, ﬁeld trials for molecular farming must be surrounded by a
50 m perimeter of land that cannot be used for food or feed production,
including livestock grazing; restrictions may be imposed on the use of
ﬁeld trial land in subsequent years for growing food or feed, or for
grazing; and disposal of plant residue after harvest must be witnessed
by an inspector of CFIA. Molecular farming in food or feed crops will
also be subject to greater isolation distances (CFIA, 2015).
4.5. Unconﬁned release
In Canada, once a plant is approved for unconﬁned environmental
release, there are limited or no conditions imposed on its release. Conse-
quently, the crop is handled and managed just like any other conven-
tionally bred commodity. For vaccine-producing plants that are not
food or feed crops, and thereforehave a considerably reduced possibility
of ending up in the food or feed supply, conditions for environmental re-
leasewould be based on a risk assessment as described above. However,
the approval of vaccine-producing food and feed crops for release is
currently limited because existing regulations require that such crops
also be approved for both food and feed use. Unlike plants that are
intended for food or feed, crops that have been modiﬁed to produce
vaccines or other therapeutic products may not be safe as food or feed
and as a result it is unlikely that they would ever be granted unconﬁned
environmental release. Consequently, such plants may be required to
grow under conditions that provide for physical and reproductive con-
ﬁnement, even during commercialization (CFIA, 2012a). Oversight
would be required throughout the life cycle of the product and condi-
tions would need to be imposed on production (CFIA, 2012c).
To address the potential risks of producing therapeutic or industrial
products in plants and their effect on the environment and the possibil-
ity of direct or indirect entry into the food and feed stream, the CFIA has
convened an inter-departmental working group to examine these
issues and explore the development of an appropriate program that
ensures that there is regulatory oversight for these products throughout
their life cycle. The work of this group is ongoing and the CFIA has
embarked on someﬁrst steps to explore a potential regulatory approach
for plants that produce industrial products. While therapeutic products
are outside of the scope of the pilot stage of this program, their future
inclusion will be considered if the program is more fully implemented.
5. Conclusions
Successful commercialization of plant-made veterinary vaccineswill
require cooperation with entrepreneurs or business associates, the
creation of a suitable business plan, and multiple stages of ﬁnancing.
The target market should be predicted well in advance as it typically
takes ﬁve to seven years to go from research to product registration;
and the ability for economical scale-up must also be assessed to deter-
mine whether the product can be produced cost-effectively at consis-
tent quality. In the ﬁeld of plant-based vaccines, intellectual property
(IP) protection and freedom to operate (FTO) are complicated by the
1580 J. MacDonald et al. / Biotechnology Advances 33 (2015) 1572–1581intricacies of the technology, and their requirements are continually
changing. Similar complications may arise when seeking product
approval, as regulatory responsibilities will be divided between various
ofﬁces and agencies, and continually change to keep pace with techno-
logical advances. While there are variations between countries in terms
of how plant-based vaccines are regulated, in general, they must be
shown to be safe, efﬁcacious, and environmentally benign in order to
gain approval.
In addition to the proof-of-concept studies typically performed in
laboratories, the commercialization of a plant-made vaccine involves
numerous steps and collaborations across various groups. These items
should be considered prior to signiﬁcant investment in a potential
product.
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